Marrakech – IM Medicare inaugurated today a new industrial unit for producing hypodermic and vaccination syringes at the Sidi Bou Othmane industrial park in the Safi-Marrakech region. Industry and Trade Minister Ryad Mezzour presided over the ceremony alongside Rehamna Province Governor Aziz Bouignane.
The MAD 85 million ($8.5 million) investment will create 70 direct jobs and boost annual production capacity to 450 million syringes. The facility targets domestic market needs while supporting Morocco’s expansion into African markets.
The project addresses national priorities for strengthening sovereignty in medical devices while contributing to socio-economic development in the Marrakech-Safi region through qualified job creation and consolidating local companies’ role in regional industrial dynamics.
“This project illustrates the capacity of Moroccan companies to innovate, produce with excellence, and establish themselves as reliable and recognized suppliers on the global vaccination device market,” Mezzour stated.
He described the facility as “the culmination of an ambitious vision aimed at positioning Morocco in strategic sectors with high added value, contributing to the development of ‘Made in Morocco’ in this sector, competitive import substitution, and consolidating our country’s health sovereignty.”
IM Medicare CEO Mohamed Idrissi Kaitouni said the new unit represents “a major development milestone for the company,” strengthening production capabilities for hypodermic and vaccination syringes while meeting international quality and safety standards.
The project operates within Morocco’s medical device sector dynamics, which shows sustained progression with 1,378 jobs, MAD 376 million ($37.6 million) in investments, MAD 903 million ($90.3 million) in revenue, and a 46% added value rate. These figures reflect the rapid multiplication of investment, activity, and wealth creation over the past 25 years.
IM Medicare was established during the COVID-19 health crisis and obtained World Health Organization (WHO) qualification certification in 2025 for its 0.5 ml self-locking syringe called “Early Activation.”
Read also: Inside the Innovation: Youssef El Azouzi Details His First-of-its-Kind Blood Filter
This recognition positions the company among global vaccination device manufacturers meeting international safety and quality standards, enabling access to international tenders, particularly those carried by international organizations active in vaccination.
Kaitouni concluded that the project reflects IM Medicare’s “commitment to contributing to national health sovereignty, satisfying local market needs, and supporting the kingdom’s opening to African markets through competitive, high-added-value production.”
